Avantor Investor Conference Presentation Deck

Supporting science from discovery to delivery Navantor™ Note: 2022E data based on full year guidance as of Q3 earnings call. All other figures represent management estimates for FY 2022. $7.5B 2022E REVENUE >85% RECURRING REVENUE >55% PROPRIETARY CONTENT >70% LIFE SCIENCE EXPOSURE 41st Annual J.P. Morgan Healthcare Conference 3

View entire presentation